US Orphan Drug Market Discussed in New KuicK Research Report Available at MarketPublishers.com06 Feb 2014 • by Natalie Aster
LONDON – The USA was the first country where a special law for governing orphan drugs – the Orphan Drug Act of 1983 – was introduced, leading to an upsurge in the popularity of orphan drug products. The FDA’s efforts to provide incentives to the pharma companies in order to attract them have been one of the key forces driving the US orphan drug sector. Currently, there are nearly 200 new drugs assigned the “orphan” status in the US annually. Most pharma giants have made their strong presence in this industry through M&As. Novartis is the only company with the maximum number of orphan designations. This company also boasts of highly successful Gleevec (imatinib) – the drug mostly used to treat multiple rare forms of cancer.
By 2018-end, the US market is most likely to see a growing number of pharma companies and orphan drug products, with some of them including the mega-blockbuster drug Rituxan from Roche, Alexion’s Soliris, and Kalydeco from Vertex. Thus, with more and more pharma companies coming into the orphan drug market and the existing players adding innovative drugs to the list in the short run, the competition in the marketplace is expected to intensify significantly, resulting in the availability of better quality drugs at lower prices.
New report “US Orphan Drug Market Outlook 2018” prepared by KuicK Research delivers comprehensive insights into most recent developments in the US orphan drug marketplace.
The study provides an deep overview of the US orphan drug market; covers criteria for orphan drug designation; reviews market specific reimbursement policies and regulatory environment; examines US orphan drug pipeline by therapeutic indication, phase, and originator company; offers a comprehensive list of marketed orphan drugs by brand name and indication. Key issues to be resolved are thoroughly discussed. The report also analyses the competitive landscape by examining the top companies in the field.
Companies mentioned: Pfizer, Roche (Genentech), Sanofi, Rare Disease Therapeutics, Glaxosmithkline, Merck, Novartis Pharmaceuticals, Alexion, Celgene, Biogen Idec, Eli Lilly (Genzyme Corporation), and Bristol Myers Squibb.
US Orphan Drug Market Outlook 2018
Published: February, 2014
Price: US$ 1,200.00
Other New Orphan Drug Market Reports Include:
More new reports by the publisher can be found at Kuick Research page.